BRIEF-Acrivon Therapeutics To Announce Clinical Update

Reuters12-17 21:43

BRIEF-Acrivon <a href="https://laohu8.com/S/LENZ">Therapeutics</a> To Announce Clinical Update

Dec 17 (Reuters) - Acrivon Therapeutics Inc ACRV.O:

ACRIVON THERAPEUTICS TO ANNOUNCE CLINICAL UPDATE ON ITS ONGOING PHASE 2B STUDIES AND PLANNED CONFIRMATORY PHASE 3 TRIAL FOR ACR-368, INITIAL CLINICAL DATA ON ACR-2316, AND OTHER AP3 PIPELINE UPDATES

Source text: ID:nGNX8xkrP7

Further company coverage: ACRV.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592918088?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 21:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592918088","market":"nz","top_or_hot":-1,"title":"BRIEF-Acrivon Therapeutics To Announce Clinical Update","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Acrivon <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> To Announce Clinical Update </title></head><body><p><span>Dec 17 (Reuters)</span><span> - </span>Acrivon Therapeutics Inc <span>ACRV.O</span>:</p><ul><li><p>ACRIVON THERAPEUTICS TO ANNOUNCE CLINICAL UPDATE ON ITS ONGOING PHASE 2B STUDIES AND PLANNED CONFIRMATORY PHASE 3 TRIAL FOR ACR-368, INITIAL CLINICAL DATA ON ACR-2316, AND OTHER AP3 PIPELINE UPDATES</p></li></ul><p>Source text: <span>ID:nGNX8xkrP7</span></p><p>Further company coverage: <span>ACRV.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Acrivon Therapeutics To Announce Clinical Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Acrivon Therapeutics To Announce Clinical Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-17 21:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Acrivon <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> To Announce Clinical Update </title></head><body><p><span>Dec 17 (Reuters)</span><span> - </span>Acrivon Therapeutics Inc <span>ACRV.O</span>:</p><ul><li><p>ACRIVON THERAPEUTICS TO ANNOUNCE CLINICAL UPDATE ON ITS ONGOING PHASE 2B STUDIES AND PLANNED CONFIRMATORY PHASE 3 TRIAL FOR ACR-368, INITIAL CLINICAL DATA ON ACR-2316, AND OTHER AP3 PIPELINE UPDATES</p></li></ul><p>Source text: <span>ID:nGNX8xkrP7</span></p><p>Further company coverage: <span>ACRV.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA34T5DX:1","article_id":"2592918088","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592918088","pubTimestamp":1765979033,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Acrivon Therapeutics To Announce Clinical Update Dec 17 (Reuters) - Acrivon Therapeutics Inc ACRV.O:ACRIVON THERAPEUTICS TO ANNOUNCE CLINICAL UPDATE ON ITS ONGOING PHASE 2B STUDIES AND PLANNED C","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ACRV":"Acrivon Therapeutics, Inc."},"translate_title":"简介-Acrivon Therapeutics宣布临床更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACRV":0.9},"content_text":"BRIEF-Acrivon Therapeutics To Announce Clinical Update Dec 17 (Reuters) - Acrivon Therapeutics Inc ACRV.O:ACRIVON THERAPEUTICS TO ANNOUNCE CLINICAL UPDATE ON ITS ONGOING PHASE 2B STUDIES AND PLANNED CONFIRMATORY PHASE 3 TRIAL FOR ACR-368, INITIAL CLINICAL DATA ON ACR-2316, AND OTHER AP3 PIPELINE UPDATESSource text: ID:nGNX8xkrP7Further company coverage: ACRV.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592918088","isCrawlerRequest":true}